Comparative Pharmacology
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus CORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus CORTISONE ACETATE.
ACETIC ACID W/ HYDROCORTISONE vs CORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetic acid exerts antibacterial and antifungal activity by lowering pH and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
None Documented
None Documented
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderateCortisone acetate + Levofloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin."
Clinical Note
moderateAcetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Category D/X
Category C
Corticosteroid
Corticosteroid
Cortisone acetate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin."